When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ACRS - Aclaris' A-101 successful in late-stage wart study
Aclaris Therapeutics Inc.
A Phase 3 clinical trial, THWART-2, evaluating Aclaris Therapeutics' (NASDAQ:ACRS) A-101 45% topical solution for the treatment of common warts met the primary endpoint of a statistically significant proportion of patients whose identified warts were clear at day 60 compared to vehicle (placebo).
More news on: Aclaris Therapeutics, Inc., Healthcare stocks news,